- Marinomed signs term sheet with Phargentis SA for a worldwide exclusive license of the Marinosolv® technology platform for an inhalation formulation.
- Partnership includes fee-for-service development, long-term milestone payments, and future royalties on product sales.
- The collaboration leverages Marinomed’s expertise to enhance solubility and bioavailability of a specialized respiratory therapeutic.
The full press release is available as download here: